US Patent

US12552836 — Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Composition of Matter · Assigned to Protagonist Therapeutics Inc · Expires 2039-07-12 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel peptide inhibitors of the interleukin-23 receptor and their related compositions and methods of use.

USPTO Abstract

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

Drugs covered by this patent

Patent Metadata

Patent number: US12552836
Jurisdiction: US
Classification: Composition of Matter
Expires: 2039-07-12
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Protagonist Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.